A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety and tolerability of increasing doses of GK
Activator (2) in patients with type 2 diabetes whose condition has not been optimally
controlled with one previous oral antihyperglycemic agent. After a 2 week washout from their
previous antidiabetic therapy, patients will receive GK Activator (2) orally, twice a day for
12 weeks, at increasing doses of 25mg bid to 200mg bid; doses will be titrated to achieve a
target fasting glucose level (FPG) of <100mg/dL. The anticipated time on study treatment is
<3 months, and the target sample size is 100-500 individuals.